|
2025
|
P/S
|
Pharmaceutical preparations and substances; Pharmaceutical preparations and substances for the tr... |
|
|
P/S
|
Health insurance information, namely, providing information regarding prescription drug insurance... |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment of cardiovascular, central nervous s... |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment of respiratory conditions and diseas... |
|
|
Invention
|
Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease. Provided h... |
|
|
Invention
|
Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease.
Provided ... |
|
|
Invention
|
Ensifentrine for the treatment of copd. The present invention relates to a compound for use in a ... |
|
|
Invention
|
Treatment.
The present invention relates to a compound for use in a method of treating chronic o... |
|
|
Invention
|
Particulate composition.
The disclosure relates to a particulate composition comprising ensifent... |
|
2024
|
Invention
|
Particulate composition. The disclosure relates to a particulate composition comprising ensifentr... |
|
|
Invention
|
Formulation production process.
The present invention relates to a process for producing a steri... |
|
|
Invention
|
Ensifentrine for use in treating chronic obstructive pulmonary disease (copd). The present invent... |
|
|
Invention
|
New treatment.
The present disclosure relates to a compound for use in treating chronic obstruct... |
|
|
Invention
|
Particulate composition comprising ensifetrine. The invention relates to a particulate compositio... |
|
|
P/S
|
Medical education and training services, namely, conducting classes and workshops and training to... |
|
|
Invention
|
Liquid pharmaceutical composition.
The invention relates to a liquid pharmaceutical composition ... |
|
|
Invention
|
Ensifentrine for treating bronchiectasis. The present invention relates to a compound for use in ... |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment
of respiratory conditions and disea... |
|
|
Invention
|
Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation.
The ... |
|
|
Invention
|
Treatment.
The present invention relates to a compound for use in a method for decreasing the fr... |
|
|
Invention
|
Treatment.
The present invention relates to a compound for use in a method of increasing trough ... |
|
|
Invention
|
Formulation production process. The present invention relates to a process for producing a steril... |
|
|
Invention
|
New treatment.
The present invention relates to a compound for use in treating moderate COPD in ... |
|
2023
|
Invention
|
Treatment of idiopathic pulmonary fibrosis with ensifentrine. The present invention relates to a ... |
|
|
Invention
|
Ensifentrine (rpl-554) for the treatment of moderate chronic obstructive pulmonary disease (copd)... |
|
|
Invention
|
Ensifentrine (rpl-554) for increasing trough lung function. The present invention relates to a co... |
|
|
Invention
|
Ensifentrine (rpl-554) for decreasing the frequency and/or severity of copd exacerbations. The pr... |
|
|
Invention
|
Liquid pharmaceutical composition. max0-taumaxmax at from about 0.6 hours to about 1.5 hours. The... |
|
|
Invention
|
Sterilization process of sterile liquid pharmaceutical composition comprising ensifentrine. The p... |
|
2021
|
Invention
|
Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate.
The present invent... |
|
|
Invention
|
Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate. The present inventi... |
|
2020
|
Invention
|
Treatment. The invention provides a compound for use in treating or preventing a disease or condi... |
|
|
Invention
|
Pharmaceutical composition comprising ensifentrine.
The present invention relates to a dry powde... |
|
|
Invention
|
Pharmaceutical composition comprising ensifentrine. The present invention relates to a dry powder... |
|
|
P/S
|
Pharmaceutical preparations and substances. Scientific research for medical purposes. Medical ser... |
|
2019
|
Invention
|
Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation. The p... |
|
|
Invention
|
Salt of a pyrimido[6,1-a]isoquinolin-4-one compound. The present invention relates to a pharmaceu... |
|
2018
|
Invention
|
Liquid inhalation formulation comprising rpl554. The present invention relates to a liquid pharma... |
|
2017
|
Invention
|
Compound and process. The present invention relates to a novel nitrile derivative of a pyrimido[6... |
|
|
Invention
|
New compound and process. The present invention relates to a novel nitrile derivative of a pyrimi... |
|
|
Invention
|
Drug combination of pde3/pde4 inhibitor and muscarinic receptor antagonist. The invention provide... |
|
2015
|
Invention
|
New treatment. The invention provides a compound for use in treating or preventing a disease or c... |
|
2014
|
Invention
|
Drug combination. 2-adrenergic receptor agonist. |
|
|
Invention
|
Drug combination. The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor ... |
|
2012
|
Invention
|
Treating cough and tussive attacks.
The invention is directed towards carcainium in the form of ... |
